AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Currently Amended) A method for treating a subject for a DTMR associated with splicing, comprising: administering to said subject an effective amount of a tetracycline compound of formula (I):

$$R^{8}$$
 R^{9}
 R^{10}
 R^{10}

wherein

R², R², R⁴, and R⁴ are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R³, R¹⁰, R¹¹ and R¹² are each hydrogen, alkyl, alkenyl, alkynyl, substituted carbonyl, or a pro-drug moiety;

R⁴ is NR⁴'R⁴", alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;

R⁵ is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

R⁶ and R⁶ are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R⁷ is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or –(CH₂)₀₋₃NR^{7c}C(=W')WR^{7a};

R⁸ is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or –(CH₂)₀₋₃NR^{8c}C(=E')ER^{8a};

R⁹ is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or -(CH₂)₀₋₃NR^{9c}C(=Z')ZR^{9a}; R^{7a} , R^{7b} , R^{7c} , R^{7d} , R^{7e} , R^{7f} , R^{8a} , R^{8b} , R^{8c} , R^{8d} , R^{8e} , R^{8f} , R^{9a} , R^{9b} , R^{9c} , R^{9d} , R^{9e} , and R^{8f} are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety; R¹³ is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; E is CR^{8d}R^{8e}, S, NR^{8b} or O; E' is O, NR^{8f}, or S; W is CR^{7d}R^{7e}, S, NR^{7b} or O: W' is O, NR^{7f} , or S; X is CHC($R^{13}Y^{2}Y^{2}$), C= $CR^{13}Y$, $CR^{6}R^{6}$, S, NR^{6} , or O; Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; Z is CR^{9d}R^{9e}, S, NR^{9b} or O: Z' is O, S, or NR^{9f}, and pharmaceutically acceptable salts, esters and enantiomers thereof, such that said DTMR associated with splicing is treated, wherein said effective amount is effective to modulate splicing.

2.-36. (Cancelled)

- 37. (Currently Amended) The method of claim $36 \underline{1}$, wherein R^2 , R^2 , R^8 , R^{10} , R^{11} , and R^{12} are each hydrogen, X is CR^6R^6 , and R^4 is NR^4 ' R^4 ", wherein R^4 ' and R^4 " are each methyl.
- 38. (Original) The method of claim 37, wherein R⁹ is hydrogen.
- 39. (Original) The method of claim 38, wherein R⁷ is substituted or unsubstituted aryl.
- 40. (Original) The method of claim 39, wherein R⁷ is substituted or unsubstituted phenyl.
- 41. (Original) The method of claim 40, wherein R⁷ is substituted with one or more substituents.

42. **(Original)** The method of claim 41, wherein said substituents are each independently alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, aryl or heterocyclic moiety.

- 43. (Original) The method of claim 38, wherein R⁷ is substituted or unsubstituted alkenyl.
- 44. (Original) The method of claim 37, wherein R^7 is substituted or unsubstituted heteroaryl and R^9 is alkyl.
- 45. (Original) The method of claim 36, wherein R⁷ is dialkylamino.
- 46. (Original) The method of claim 45, wherein R⁹ is alkylamino.
- 47. (Original) The method of claim 45, wherein R^9 is $-NR^{9c}C(=Z')ZR^{9a}$, wherein R^{9c} is hydrogen, Z' is nitrogen or oxygen, Z is NH, and R^{9a} is aryl or aralkyl.

48.-53. (Cancelled)

54. (Currently Amended) The method of claim 1, wherein said tetracycline compound is a tetracycline compound of Table 2 selected from the group consisting of:

Application No.: 10/692,764 Docket No.: PAZ-205CP Examiner: K.A. Makar Group Art Unit: 1636

Application No.: 10/692,764 Docket No.: PAZ-205CP Examiner: K.A. Makar Group Art Unit: 1636

Application No.: 10/692,764 Docket No.: PAZ-205CP Examiner: K.A. Makar Group Art Unit: 1636

Application No.: 10/692,764 Docket No.: PAZ-205CP Examiner: K.A. Makar Group Art Unit: 1636

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \\ \\ \\ \end{array} \end{array}$$

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \end{array} \end{array}$$

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \\ \\ \\ \\ \end{array} \end{array}$$

Application No.: 10/692,764 Docket No.: PAZ-205CP Examiner: K.A. Makar Group Art Unit: 1636

Application No.: 10/692,764

Examiner: K.A. Makar

Docket No.: PAZ-205CP

Group Art Unit: 1636

$$\begin{bmatrix} \frac{1}{2} & \frac{$$

Application No.: 10/692,764

Examiner: K.A. Makar

$$\begin{array}{c|c} & \underline{H} & \underline{H} & \underline{N} \\ \hline \\ OH & O & OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array} \\ \begin{array}{c} OH \\ OH \\ OH \\ \end{array}$$

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ \hline OH & O & OH \\ \hline \end{array} \begin{array}{c} & & \\ \hline OH \\ \hline OH \\ \hline \end{array} \begin{array}{c} & \\ \hline OH \\ \hline \end{array} \begin{array}{c} OH \\ \hline OH \\ \hline \end{array} \begin{array}{c} OH \\ \hline OH \\ \hline \end{array}$$

Docket No.: PAZ-205CP

Group Art Unit: 1636

Application No.: 10/692,764

Examiner: K.A. Makar

oh o Lohl

0 ÓН

Docket No.: PAZ-205CP Group Art Unit: 1636

) O

ÓН

NH₂

0

OH O

OH O

CH₃

NH₂

O

OH O

ÓН н₄С

Docket No.: PAZ-205CP

Group Art Unit: 1636

NH₂

OH O

ÒН

Application No.: 10/692,764

OH O

ÒН

Examiner: K.A. Makar

ÓН

Docket No.: PAZ-205CP Group Art Unit: 1636

ÓН

Docket No.: PAZ-205CP Group Art Unit: 1636

_ J º베

όн

Application No.: 10/692,764

Examiner: K.A. Makar

Docket No.: PAZ-205CP Application No.: 10/692,764 Examiner: K.A. Makar Group Art Unit: 1636

ÒН

OH OH

OH O

NH₂

0

όн

ÓН

Application No.: 10/692,764

Docket No.: PAZ-205CP Group Art Unit: 1636

Examiner: K.A. Makar

Application No.: 10/692,764 Docket No.: PAZ-205CP Examiner: K.A. Makar

Group Art Unit: 1636

and pharmaceutically acceptable salts thereof.

55. (Cancelled)

56. (Cancelled)

57. (Currently Amended) The method of claim 1, wherein said tetracycline compound

, and pharmaceutically acceptable salts thereof.

- 58. (New) The method of claim 1, wherein said effective amount is effective to modulate splicing of said subject's RNA.
- 59. (New) The method of claim 58, wherein said modulation of splicing increases splicing or RNA.
- 60. (New) The method of claim 58, wherein said modulation of splicing decreases splicing of RNA.
- 61. (New) The method of claim 58, wherein said RNA is mRNA.
- 62. (New) The method of claim 1, wherein said subject is an animal.
- 63. (New) The method of claim 1, wherein said DMTR associated with splicing is cystic fibrosis, muscular dystrophy, eosinophilic diseases, frontotemporal dementia with parkinsonism, a neurodegenerative disorder or β -thalassemia.
- 64. (New) The method of claim 1, wherein said 68, wherein said modulation of splicing is activation of cryptic splice sites, silencing of consensus splice sites, silencing of exonic or intronic splicing enhancers (ESEs or ISEs), silencing of exonic or inronic splicing silencers (ESSs or ISSs),

alteration of the binding or a component of the splicing machinery to the RNA, or the affecting of intermolecular interactions between components of the splicing machinery.